Concepedia

Megan McMahon

MM

5

Publications

125

Citations

5

H-Index

2018

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

AstraZeneca (United Kingdom)

Pfizer (United States)

Vertex Pharmaceuticals (United States)

Janssen (Belgium)

Megan McMahon is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, transplantation medicine, and kidney transplant.

ORCID

Top concepts

Publications per year

2018–2021

5

Publications

5

Establishing Patient Centric Specifications for Drug Substance and Drug Product Impurities

Joel P. Bercu, Susan C. Berlam, John C. Berridge et al. · Journal of Pharmaceutical Innovation · 2018 · 39 citations · Full text

Exploring cancer survivors’ attitudes, perceptions, and concerns about using medical cannabis for symptom and side effect management: A qualitative focus group study

David Victorson, Megan McMahon, Bruriah Horowitz et al. · Complementary Therapies in Medicine · 2019 · 31 citations

, , +13

Considerations for Updates to ICH Q1 and Q5C Stability Guidelines: Embracing Current Technology and Risk Assessment Strategies

Megan McMahon, Alexander Abbott, Yelizaveta Babayan et al. · The AAPS Journal · 2021 · 27 citations

, , +4

Utilization of risk-based predictive stability within regulatory submissions; industry’s experience

Megan McMahon, Helen Elizabeth Williams, Elke Debie et al. · AAPS Open · 2020 · 18 citations · Full text

Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report

Aaron P. Pearston, Amanda I. Ingemi, Kathryn Ripley et al. · Transplantation Proceedings · 2021 · 10 citations

, , +8

Rows per page

1–5 of 5